Mineralys Therapeutics (MLYS)
Develops lorundrostat for uncontrolled hypertension and related cardiorenal conditions.
Something off on this page? Send us feedback.
Develops lorundrostat, an oral aldosterone synthase inhibitor under FDA review for hypertension, with related clinical work in chronic kidney disease and obstructive sleep apnea. The pre-commercial business depends on a single licensed candidate and would earn product revenue only after regulatory approval and launch.
Develops lorundrostat, an oral aldosterone synthase inhibitor intended to reduce aldosterone production for hypertension and related cardiorenal conditions. The primary U.S. program targets adults whose blood pressure remains uncontrolled or resistant despite other medicines, while Explore-CKD and Explore-OSA have tested the same candidate in patients with chronic kidney disease or obstructive sleep apnea.
Completed the Launch-HTN and Advance-HTN pivotal studies, submitted lorundrostat for FDA review, and is building U.S. commercial capabilities ahead of a possible launch. Transform-HTN continues to collect longer-term safety and efficacy data.
Holds exclusive worldwide rights under a license from Tanabe Pharma and relies on outside manufacturers and clinical contractors. Lorundrostat remains its only product candidate; it has no approved products or product revenue, making regulatory approval and commercialization the business's central dependencies.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Mar 13, 2026 | Jefferies | Target | $30 | |
| Mar 10, 2026 | H.C. Wainwright | Target | $52 | $56 |
| Dec 19, 2025 | Stifel Nicolaus | Target | $52 | |
| Oct 30, 2025 | H.C. Wainwright | Target | $42 | $52 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $661.4M · Total debt $97.6M · Total assets $667.9M · Shareholders' equity $550.9M
- Revenue
- $0
- Operating income
- −$246.0M
- Net income
- −$241.1M
No dividends on record.
| Institutions241 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 112.17% | 99.16M shares | |
| Insiders11 holders · as of Aug 25, 2026 | 8.83% | 7.81M shares | |
| Strategic holders1 holder · as of Mar 17, 2025 | 6.42% | 5.67M shares | |
| Adds to | 127.42% |
88.41M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 127.42%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Catalys Pacific Fund, LPInstitution | 9.05% | 8.00M | 13Gfiled Feb 13, 2026 ↗ |
Catalys Pacific, LLCInstitution | 8.94% | 7.90M | 13Fas of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 8.70% | 7.69M | 13Fas of Jun 30, 2026 |
Srinivas AkkarajuInsider | 7.18% | 6.35M | 13Dfiled Sep 8, 2025 ↗ |
BlackRock, Inc.Institution | 6.66% | 5.89M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Eric Warren | officer: Chief Commercial Officer | −7,437 | $25.98 |
| Aug 10, 2026 | David Malcom Rodman | officer: Chief Medical Officer | −2,170 | $27.09 |
| Jul 21, 2026 | Eric Warren | officer: Chief Commercial Officer | −7,438 | $26.87 |
| Jul 17, 2026 | David Malcom Rodman | officer: Chief Medical Officer | −416 | $26.53 |
| Jul 15, 2026 | David Malcom Rodman | officer: Chief Medical Officer | −6,349 | $26.61 |
- AstraZeneca (ADR)
Oral ASI Baxfendy competes head-to-head in the same uHTN/rHTN add-on market.
- Alnylam Pharmaceuticals
RNAi zilebesiran in Phase 3 ZENITH targets uHTN add-on with biannual dosing.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics | $29.18 | +0.45% | $2.56B | — | — | — | — |
| AstraZeneca (ADR) | $163.56 | +1.18% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Alnylam Pharmaceuticals | $265.22 | −0.74% | $35.78B | 45.2 | 31.5 | 7.4 | +66.9% |
| Median | 34.7 | 23.4 | 5.8 | +36.6% |